Bengaluru, Karnataka, India, Sep 18, 2017
This is to inform you that the US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh from Sep 11 to 15, 2017 and completed the audit without any observations. No form 483 was issued. The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities.
– Company Spokesperson
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Download Company Statement